Lead Effects on the Heme Biosynthetic Pathway Relationship to Toxicity
1987; Wiley; Volume: 514; Issue: 1 Linguagem: Inglês
10.1111/j.1749-6632.1987.tb48774.x
ISSN1749-6632
AutoresMichael Moore, Abraham Goldberg, ALBERT A. C. YEUNG‐LAIWAH,
Tópico(s)Hemoglobinopathies and Related Disorders
ResumoAnnals of the New York Academy of SciencesVolume 514, Issue 1 p. 191-203 Lead Effects on the Heme Biosynthetic Pathway Relationship to Toxicity MICHAEL R. MOORE, MICHAEL R. MOORE University Department of Medicine Gardiner Institute Western Infirmary Glasgow, ScotlandSearch for more papers by this authorABRAHAM GOLDBERG, ABRAHAM GOLDBERG University Department of Medicine Gardiner Institute Western Infirmary Glasgow, ScotlandSearch for more papers by this authorALBERT A. C. YEUNG-LAIWAH, ALBERT A. C. YEUNG-LAIWAH Department of Pharmacology and Internal Medicine University of Alberta Edmonton, CanadaSearch for more papers by this author MICHAEL R. MOORE, MICHAEL R. MOORE University Department of Medicine Gardiner Institute Western Infirmary Glasgow, ScotlandSearch for more papers by this authorABRAHAM GOLDBERG, ABRAHAM GOLDBERG University Department of Medicine Gardiner Institute Western Infirmary Glasgow, ScotlandSearch for more papers by this authorALBERT A. C. YEUNG-LAIWAH, ALBERT A. C. YEUNG-LAIWAH Department of Pharmacology and Internal Medicine University of Alberta Edmonton, CanadaSearch for more papers by this author First published: December 1987 https://doi.org/10.1111/j.1749-6632.1987.tb48774.xCitations: 44AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL References 1 STOKVIS, B. J. 1985. Zur pathogenese der hämatoporphyrinurie. Z. Klin. Med. 28: 1– 21. 2 DUESBERG, R. 1931. Über die Anämien. I. Porphyrie und Erythropoese. Arch. Exp. Pathol. 162: 249. 3 GROTEPASS, W. 1932. Zur Kenntnis des im Harn auftretenden Porphyrins bei Bleivergiftung. Hoppe-Seyler's Z. Physiol. Chera. 205: 193– 197. 4 HAEGER-ARONSEN, B. 1960. Studies in urinary excretion of δ-aminolaevulinic acid and other haem precursors in lead workers and lead-intoxicated rabbits. J. Clin. Lab. Invest. 12(Suppl. 47): 1– 28. 5 MOORE, M. R. & A. GOLDBERG. 1985. Health implications of the hematopoietic effects of lead. In Dietary and Environmental Lead: Human Health Effects. K. R. Mahaffey, Ed.: 261– 299. Elsevier. Amsterdam . 6 CHEH, A. & J. B. NEILANDS. 1973. Zinc: An essential metal ion for beef liver δ-aminolevulinate dehydratase. Biochem. Biophys. Res. Commun. 55: 1060– 1063. 7 ABDULLA, M. & B. HAEGER-ARONSEN. 1971. ALA dehydratase activation by zinc. Enzyme 12: 708– 710. 8 BOUDÈNE, C. I., N. DESPAUX-PAGES, E. COMOY & C. I. BOHUON. 1984. Immunological and enzymatic studies of erythrocytic 5-aminolaevulinate dehydratase: Comparison of results obtained in normal and lead-exposured subjects. Int. Arch. Occup. Environ. Health 55: 87– 96. 9 GOLDBERG, A. & M. R. MOORE. 1980. The porphyrias. In Clinics in Haematology 9. Saundcrs. London . 10 MEREDITH, P. A. & M. R. MOORE. 1979. The influence of lead on haem biosynthesis and biodegradation in the rat. Biochem. Soc. Trans. 7; 637– 639. 11 MOORE, M. R. & A. GOLDBERG. 1980. Lead and heme biosynthesis. In Lead Toxicity. R. L. Singhal & J. A. Thomas, Eds.: 79– 117. Urban and Schwartzenberg. Baltimore , MD . 12 MCGILION, F. B., M. R. MOORE & A. GOLDBERG. 1975. Some pharmacological effects of δ-aminolaevulinic acid on blood pressure in the rat and on rabbit isolated ear arteries. Clin. Exp. Pharmacol. Physiol. 2: 365– 371. 13 SHANLEY, B. C., A. C. NEETHLING, V. A. PERCY & H. CARSTENS. 1975. Neurochemical aspects of porphyria. I. Studies on the possible neurotoxicity of δ-aminolaevulinic acid. S. Afr. Med. J. 49: 576– 680. 14 MEREDITH, P. A., M. R. MOORE, B. C. CAMPBELL, G. G. THOMPSON & A. GOLDBERG. 1978. δ-Aminolaevulinic acid metabolism in normal and lead-exposed humans. Toxicology 9: 1– 9. 15 PERCY, V. A., M. C. L. LAMM & J. J. F. TALJAARD. 1981. δ-Aminolaevulinic acid uptake, toxicity and effect on [14C]γ-aminobutyric acid uptake into neurons and glia in culture. J. Neurochem. 36: 69– 76. 16 JARRETT, A., C. RIMINGTON & D. A. WILLOUGHBY. 1956. 5-Aminolaevulinic acid and porphyria. Lancet i: 125– 127. 17 MCGILLION, F. B., M. R. MOORE & A. GOLDBERG. 1972. The effects of γ-aminolaevulinic acid on the spontaneous activity of mice. Scott. Med. J. 18: 133– 134. 18 CUTLER, M. G., M. R. MOORE & F. G. EWART. 1979. Effects of δ-aminolaevulinic acid administration on social behavior in the laboratory mouse. Psychopharmacology 61: 131– 135. 19 SIMA, A. A. F., J. C. KENNEDY, D. BLAKESLEE & D. M. ROBERTSON. 1981. Experimental porphyric neuropathy: A preliminary report. Can. J. Neurol. Sci. 8: 105– 114. 20 BERLIN, N. I., A. NEUBERGER & J. J. SCOTT. 1956. The metabolism of 5-aminolaevulinic acid. II. Normal pathways studied with the aid of 14C. J. Biochem. 64: 90– 100. 21 MEYER, U. S., L. J. STRAND, M. DOSS, A. C. REES & H. S. MARVER. 1972. Intermittent acute porphyria: Demonstration of a genetic defect in porphobilinogen metabolism. N. Engl. J. Med. 286: 1277– 1282. 22 MOORE, M. R. & P. A. MEREDITH. 1976. The association of δ-aminolaevulinic acid with the neurological and behavioural effects of lead exposure. In Trace Substances in Environmental Health X. D. D. Hemphill, Ed.: 363– 371. University of Missouri Press. Columbia , MO . 23 PIERACH, C. A. & P. S. EDWARDS. 1978. Neurotoxicity of δ-aminolaevulinic acid and porphobilinogen. Exp. Neurol. 62: 810– 814. 24 DISLER, P. B. & M. R. MOORE. 1985. Porphyria. In Clinics in Dermatology. Vol. 3: 1– 163. Lippincott. Philadelphia , PA . 25 GENTZ, J., S. JOHANSSON, S. LINDBLAD, S. LINDSTEDT & R. ZETTERSTROM. 1969. Excretion of δ-aminolaevulinic acid in hereditary tyrosinaemia. Clin. Chim. Acta 23: 257– 263. 26 SlLBERGELD, E. K., R. E. HRUSKA, D. BRADLEY, J. M. LAMON & B. C. FRYKHOLM. 1982. Neurotoxic aspects of porphyrinopathies: Lead and succinylacetone. Environ. Res. 29: 459– 471. 27 SASSA, S. & A. KAPPAS. 1983. Hereditary tyrosinemia and the heme biosynthetic pathway: Activity by succinyl acetone. J. Clin. Invest. 71: 625– 634. 28 LOOTS, J. M., D. M. BECKER, B. J. MEYER, N. GOLDSTUCK & S. KRAMER. 1975. The effect of porphyrin precursors on monosynaptic reflex activity in the isolated hemisecreted frog spinal cord. J. Neurol. Trans. 36: 71– 81. 29 NICHOLL, R. A. 1976. The interaction of porphyrin precursors with GABA receptors in the isolated frog spinal cord. Life Sci. 19: 521– 526. 30 CUTLER, M. G., M. MCLAUGHLIN, E. MCNEIL & M. R. MOORE. 1985. Effects of δ-aminolaevulinic acid on contractile activity in the isolated small intestine of the rabbit. Neuropharmacology 24: 1005– 1009. 31 CUTLER, M. G., J. M. DICK & M. R. MOORE. 1978. Effect of δ-aminolaevulinic acid on frog nerve-muscle function. Life Sci. 23: 2233– 2238. 32 FELDMAN, D. S., R. D. LEVERE & J. S. LIEBERMAN. 1968. Presynaptic neuromuscular inhibition by δ-aminolaevulinic acid, a porphyrin precursor. Trans. Am. Neurol. Assoc. 93: 206– 208. 33 BORNSTEIN, J. C., J. B. PICKETT & I. DIAMOND. 1979. Inhibition of the evoked release of acetylcholine by the porphyrin precursor, δ-aminolaevulinic acid. Ann. of Neurol. 5: 94– 96. 34 MOORE, M. R., F. B. MCGILLION & A. GOLDBERG. 1976. Some pharmacological and behavioural effects of δ-aminolaevulinic acid. In Porphyrins in Human Diseases. M. Doss, Ed.: 148– 154. Karger. Basel . 35 BECKER, D. M., N. GOLDSTUCK & S. KRAMER. 1975. Effect of δ-aminolaevulinic acid on the resting membrane potential of frog sartorius muscle. S. Afr. Med. J. 49: 1790– 1792. 36 SWEENEY, V. P., M. A. PATHAK & A. K. ASBURY. 1970. Acute intermittent porphyria: Increased ALA synthetase activity during an attack. Brain 93: 369– 380. 37 BONKOWSKY, H. L., D. P. TSCHUDY, A. COLLINS, J. DOHERTY, I. BOSSENMAIER, R. CARDINAL & C. J. WATSON. 1971. Repression of the overproduction of porphyrin precursors in acute intermittent porphyria by intravenous infusions of hematin. Proc. Natl. Acad. Sci. USA 68: 2725– 2729. 38 WALKER, J. E. 1983. Glutamate, GABA and CNS disease: A review. Neurochem. Res. 8: 521– 550. 39 MULLER, W. E. & S. H. SNYDER. 1977. δ-Aminolaevulinic acid influences on synaptic GABA receptor-binding may explain CNS symptoms of porphyria. Ann. Neurol. 2: 340– 342. 40 DICHTER, H. N., L. TADDEINI, S. LIN & G. F. AYALA. 1977. δ-Aminolaevulinic acid: Effects of porphyrin precursor on an isolated neuronal preparation. Brain Res. 126: 189– 195. 41 BECKER, D. M., D. VILJOEN & S. KRAMER. 1976. Porphyrin precursors and their effect in vitro in some aspects of nerve function. In Porphyrins in Human Disease. M. Doss, Ed.: 163– 172. Karger. Basel . 42 RUSSELL, V. A., M. C. L. LAMM & J. J. F. TALJAARD. 1983. Inhibition of Na+, K+ATPase activity by 5-aminolaevulinic acid. Neurochem. Res. 8: 1407– 1415. 43 BRENNAN, M. J. W., R. C. CANTRILL & S. KRAMER. 1980. Effect of δ-aminolaevulinic acid on GABA receptor-binding in synaptic plasma membranes. Int. J. Biochem. 12: 833– 835. 44 BRENNAN, M. J. W. & R. C. CANTRILL. 1979. The effect of δ-aminolaevulinic acid on the uptake and efflux of [3H]GABA in rat brain synaptosomes. J. Neurochem. 32: 1781– 1786. 45 GOLDBERG, A., W. D. H. PATON & S. W. THOMPSON. 1954. Pharmacology of porphyrins and porphobilinogen. Br. J. Pharmacol. 9: 91– 99. 46 MOORE, M. R., K. E. L. MCCOLL, C. RIMINGTON & A. GOLDBERG. 1987. Disorders of Porphyrin Metabolism. Plenum. New York , NY . 47 RIOPELLE, R. J. & J. C. KENNEDY. 1982. Some aspects of porphyrin neurotoxocity in vitro. Can. J. Physiol. Pharmacol. 60: 707– 714. 48 SELMAN, S. H., M. KREIMER-BIRNBAUM, J. E. KLAUNIG, P. J. GOLDBLATT, R. W. KECK & S. L. BRITTON. 1984. Blood flow in transplantable bladder tumors treated with hematoporphyrin derivative and light. Cancer. Res. 44: 1924– 1927. 49 LIM, H. W., L. YOUNG, M. HAGAN & I. GIGLI. 1985. Delayed phase of hematoporphyrininduced phototoxicity: Modulation by complement, leuocyctes and antihistamines. J. Invest. Dermatol. 84: 114– 117. 50 AVNER, D. L., R. LARSEN & M. M. BERENSON. 1983. Inhibition of liver surface membrane Na+, K+-adenosine triphosphatase, Mg2+-adenosine triphosphatase and 5-nucleotidase activities by protoporphyrin. Gastroenterology 85: 700– 706. 51 DUBBLEMAN, T. M., A. F. DE GOEIJ & J. VAN STEVENINCK. 1980. Protoporphyrin-induced photodynamic effects on transport processes across the membrane of human erythrocytes. Biophys. Acta 595: 133– 139. 52 CULTER, M. G. & S. ARROL. 1987. Pharmacological effects of haem biosynthetic intermediates in isolated intestinal preparations. Eur. J. Pharmacol. 134: 249– 256. 53 IGNARRO, L. J., K. S. WOOD & M. S. WOLIN. 1982. Activation of purified soluble guanylate cyclase by protoporphyrin IX. Proc. Natl. Acad. Sci. USA 79: 2870– 2873. 54 LACOMBE, M. L. & C. EBERENTZ-LHOMME. 1983. Protoporphyrin IX activates the Mg2+-dependent guanylate cyclase from rat liver plasma membranes. Biochem. Biophys. Res. Commun. 116: 47– 53. 55 WHETSELL, W. O., S. SASSA, D. BICKERS & A. KAPPAS. 1978. Studies on porphyrin-heme biosynthesis in organotypic cultures of chick dorsal root ganglion. I. Observations on neuronal and nonneuronal elements. J. Neuropathol. Exp. Neurol. 37: 497– 507. 56 PATERNITI, J. R., J. J. SIMONE & D. S. BEATTIE. 1978. Detection and regulation of δ-aminolaevulinic acid synthetase activity in the rat brain. Arch. Biochem. Biophys. 189: 96– 101. 57 SASSA, S., G. L. ZALAR & A. KAPPAS. 1978. Studies in porphyria. VII. Induction of uroporphyrinogen I synthase and expression of the gene defect of acute intermittent porphyria in mitogen-stimulated human lymphocytes. J. Clin. Invest. 61: 499. 58 PERCY, V. A. & B. C. SHANLEY. 1979. Studies on haem biosynthesis in rat brain. J. Neurochem. 33: 1267– 1274. 59 DE MATTEIS, F., P. ZETTERLUND & L. WETTERBERG. 1981. Brain 5-aminolaevulinate synthase: Developmental aspects and evidence for a regulatory role. Biochem. J. 196: 811– 817. 60 BISSELL, D. M. & L. E. HAMMAKER. 1977. Effect of endotoxin on tryptophan pyrrolase and δ-aminolaevulinate synthase: Evidence for an endogenous regulatory heme fraction in rat liver. J. Biochem. 166: 301– 304. 61 DE MATTEIS, F. & R. E. RAY. 1982. Studies on cerebellar haem metabolism in the rat in vivo. J. Neurochem. 39: 551– 556. 62 BADAWY, A. A. B. & M. EVANS. 1975. Regulation of rat liver tryptophan pyrrolase by its cofactor haem: Experiments with haematin and 5-aminolaevulinate and comparison with the substrate and hormonal mechanisms. Biochem. J. 150: 511– 520. 63 BADAWY, A. A. B., A. N. WELCH & C. J. MORGAN. 1981. Tryptophan pyrrolase in haem regulation. Biochem. J. 198: 309– 314. 64 LUDWIG, G. D. & I. S. EPSTEIN. 1961. A genetic study of two families having the acute intermittent type of porphyria. Ann. Intern. Med. 55: 81– 90. 65 LITMAN, D. A. & M. A. CORREIA. 1985. Elevated brain tryptophan and enhanced 5-hydroxytryptamine turnover in acute hepatic heme deficiency: Clinical implications. J. Pharmacol. Exp. Ther. 232: 337– 345. 66 BIRNIE, G. G., K. E. L. MCCOLL, G. G. THOMPSON, M. R. MOORE, A. GOLDBERG & M. J. BRODIE. 1987. Antipyrine metabolism in acute hepatic porphyria in relapse and remission. Br. J. Clin. Pharmacol. 23: 358– 361. 67 GOLDBERG, A., D. DOYLE, A. C. YEUNG-LAIWAH, M. R. MOORE & K. E. L. MCCOLL. 1985. A study of cytochrome oxidase activity in muscle biopsies from patients with acute intermittent porphyria. Q. J. Med. 57: 799. 68 YEUNG-LAIWAH, A. A. C., M. R. MOORE & A. GOLDBERG. 1987. Pathogenesis of acute porphyria. Q. J. Med. 63: 377– 392. 69 BULL, R. J. 1980. Lead and energy metabolism. In Lead Toxicity. R. L. Singhal & J. A. Thomas, Eds.: 119– 167. Urban and Schwartzenberg. Baltimore , MD . 70 BONKOWSKY, H. L., D. P. TSCHUDY, E. C. WEINBACH, P. S. EBERT & J. M. DOHERTY. 1975. Porphyrin synthesis and mitochondrial respiration in acute intermittent porphyria: Studies using cultured human fibroblasts. J. Lab. Clin. Med. 85: 93– 102. 71 DA PALMA-CARLOS, A. G. 1968. A regulasao da biossintesa das porfirinas e do heme. Ph. D. diss. Lisbon. 72 LABBE, R. F., J. NUTTER, M. L. COWGER & L. D. NIELSEN. 1970. Control of heme biosynthesis: Effect of nicotinamide adenine dinucleotide on the induction of δ-aminolaevulinate synthetase. Biochem. Med. 3: 465– 474. 73 GAJDOS, A. & M. GAJDOS-TOROK. 1969. The quantitative regulation of the biosynthesis of porphyrins by intracellular ATP concentration. Biochem. Med. 2: 372– 388. 74 ARRESE, M. R., D. VOJENSKY & J. MATTOON. 1982. Characterisation of a cytochrome oxidase-deficient yeast mutant which accumulates porphyrins. Biochem. Biophys. Res. Commun. 107: 848– 855. 75 GOPALAN, G., J. JAYARAMAN & C. RAJAMANICKAN. 1984. Effect of exogenous addition of hemin on the biogenesis of mitochondrial membranes during glucose repression of Saccharomyces cerveisiae. Arch. Biochem. Biophys. 235: 159– 166. Citing Literature Volume514, Issue1Mechanisms of Chemical‐Induced PorphyrinopathiesDecember 1987Pages 191-203 ReferencesRelatedInformation
Referência(s)